AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06794333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rezum Vapor Therapy
Description: The treatment involves the insertion of a radiofrequency needle into the prostate tissue and the emission of water vapor. Treatment under local anesthesia/sedation. Treatment planning using the REZUM device, with the number of injections proportional to the recommended therapeutic scheme based on prostate volume (1 injection every centimeter starting 1 cm below the bladder neck and 1 cm in front of the verumontanum). Water vapor emission for 9-second intervals with a maximum of 9 applications per patient. Three-way bladder catheter to decrease local temperature. The bladder catheter will be removed 15 days after patient discharge. Regarding the REZUM, it is a system that uses sterile single-use handpieces available within the company, where a special optics is inserted for direct visualization. The handpiece features a device that allows the manual insertion of a needle into the prostate, from which water vapor is emitted for the described treatment.
Study NCT06795854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Sessions will be conducted 3 times per week. Each 40-minute session will include a 5-minute warm-up involving fast walking, slow running, and stretching, followed by an active phase of continuous running. The running period will start at 15 minutes and increase by 2 minutes every two sessions until reaching 30 minutes. The session will conclude with a 5-minute cool-down of slow running and stretching. Exercise intensity will be maintained at 13-15 on the Borg Rate of Perceived Exertion, with continuous walking performed on a treadmill.
Study NCT06795854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Description: Relaxation techniques will include slow deep breathing and mindfulness meditation exercises. The breathing exercise will involve six cycles per minute, with a 4-second inhalation and a 6-second exhalation, repeated for 30 minutes, three sessions per week. Mindfulness meditation will include a stress and pain management program with sessions starting at 10-15 minutes and gradually increasing to 20-30 minutes, three times per week. Sessions will be conducted in a quiet, comfortable space, focusing on breath awareness, body scanning, thought observation, and optional loving-kindness meditation, concluding with a reflection period.
Study NCT06795854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fodmap diet
Description: All groups will follow a low-FODMAP diet (LFD). The LFD will exclude foods that commonly aggravate IBS symptoms, such as those containing lactose (dairy), fructose (e.g., apples, pears), and sweeteners like sorbitol and xylitol. Female participants with a BMI of 25 to 29 will aim for a daily calorie intake of 1,800 to 2,200 calories, adjusted based on age, activity level, and metabolism, to maintain weight while managing IBS symptoms effectively.
Study NCT06795854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fodmap diet
Description: All groups will follow a low-FODMAP diet (LFD). The LFD will exclude foods that commonly aggravate IBS symptoms, such as those containing lactose (dairy), fructose (e.g., apples, pears), and sweeteners like sorbitol and xylitol. Female participants with a BMI of 25 to 29 will aim for a daily calorie intake of 1,800 to 2,200 calories, adjusted based on age, activity level, and metabolism, to maintain weight while managing IBS symptoms effectively.
Study NCT06795087 — intervention group
Intervention type: OTHER
Intervention: Opioid Medication Disposal Education
Description: Education on opioid medication disposal will be provided in the form of a pamphlet created by Atrium Health based on FDA resources and will be given to all participants at discharge (cystectomy, nephrectomy, prostatectomy) beginning in the second year, approximately 13 months from when the first participant is enrolled or until a minimum of 100 evaluable participants are enrolled in the pre-education cohort, whichever occurs last.
Study NCT06795633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holistic Care Program for High-Risk Pregnancies
Description: High-risk pregnant women admitted to the perinatology clinic participated in the Holistic Care Program for High-Risk Pregnancies in addition to the midwifery care provided in the clinic.
Study NCT06788951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: administration of oral carbohydrate solution to patients before coronary artery bypass graft surgery
Description: Oral carbohydrate solution will be administered to patients before coronary artery bypass graft operation and its effects on postoperative nausea-vomiting, hunger, thirst, physiological parameters and recovery will be evaluated.
Study NCT06788951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: giving flavored water to patients before coronary artery bypass graft surgery
Description: The effects of flavored water given to patients before coronary artery bypass graft operation on postoperative nausea-vomiting, hunger and thirst,
Study NCT06796153 — intervention group
Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
Study NCT06796153 — intervention group
Intervention type: OTHER
Intervention: Visible Light Exposure - Untreated zone
Description: The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
Study NCT06795451 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous spinal direct current stimulation
Description: transcutaneous spinal direct current stimulation
Study NCT06795451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous spinal direct current stimulation
Description: transcutaneous spinal direct current stimulation
Study NCT06788847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided needle knife dissection
Description: This procedure involves a minimally invasive dissection of the fibrous cords in Dupuytren's Contracture using a needle knife guided by ultrasound imaging. Local anesthesia using 3-5 ml of 1% Lidocaine and 0.25% bupivacaine is administered for patient comfort. The technique aims to improve precision, minimize complications and reduce recurrence.~Device: Sonosite M-Turbo Ultrasound Machine with Linear Probe HFL38x (6-13 MHz) is used for real-time imaging during the procedure.
Study NCT06794398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-CPR inside a room when the lay responder is alone (no operator for holding the phone)
Description: Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.
Study NCT06794398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-CPR in a yard (outside environment) when the lay responder is alone (no operator for holding the phone)
Description: Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.
Study NCT06796205 — intervention group
Intervention type: OTHER
Intervention: Treated zones exposed with Visible Light source
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
Study NCT06796205 — intervention group
Intervention type: OTHER
Intervention: Untreated zone exposed with Visible Light source
Description: The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
Study NCT06795477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No MI Help
Description: Participants will complete the medication verification task without any MI help
Study NCT06795477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretable MI
Description: Participants receive interpretable machine intelligence assistance to complete the medication verification tasks.
Study NCT06795477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterpretable MI
Description: Participants receive uninterpretable (i.e., black-box) machine intelligence assistance to complete the medication verification tasks.
Study NCT06792851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kosmos Bladder Volume Algorithm
Description: Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer pre-void. Participants voided and measured void volume. Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer post-void. Kosmos calculated volume measurements were compared to volume measurements calculated using calipers placed by sonographers by hand.
Study NCT06793553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction therapy
Description: 2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX
Study NCT06793553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction therapy
Description: 2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX
Study NCT06793982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Joint Injection
Description: Magellan Autologous Concentration System, ISTO Biologics
Study NCT06793982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: 5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
Study NCT06794073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal Thermal Therapy
Description: The high-burden tumor is identified as the target lesion for treatment. A pre-treatment biopsy of the target lesion is performed to obtain tumor tissue. Multimodal ablation therapy of the target lesion is conducted under CT guidance. The treatment procedure follows the tumor ablation protocol using the multimodal therapy radiofrequency temperature-controlled mode.
Study NCT06241209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PowerPoint program visual stimulation
Description: Moving objects, food, money, and other targets will be presented in the remaining seeing, and hemianopic areas.
Study NCT06796920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Upon completion of the initial assessments, a lumbar spinal cord nerve stimulator and pulse generator will be implanted. Following surgery, based on the patient's recovery status, the patient will be transferred to the respective center for rehabilitation within one to two weeks. Afterward, electrical stimulation therapy will be initiated. Stimulation should be applied at least three days per week. Each day, the total stimulation time should be between 4 and 8 hours. Stimulation Modes: Continuous Stimulation: For example, if 6 hours of stimulation are prescribed, the stimulator will run uninterrupted for 6 hours. Intermittent Stimulation: For instance, a cycle of 40 seconds on and 20 seconds off. If a total of 6 hours of active stimulation is needed, the stimulator must remain on for 9 hours in total to accommodate rest intervals.The ranges for each parameter are as follows:Stimulation Frequency: 2 Hz - 2000 Hz, Pulse Width: 20 μs - 1000 μs, Stimulation Amplitude:Voltage: 0 V - 10 v
Study NCT05969860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Encounter
Description: Receive treatment in clinic
Study NCT05969860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Health Encounter
Description: Receive at-home treatment
Study NCT05969860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05969860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03440086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: abdominal Jackson-Pratt drain
Description: One-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
Study NCT06083272 — intervention group
Intervention type: DEVICE
Intervention: Vitalthings Guardian M10 fixed and M10 mobile
Description: VitalThings Guardian M10 / M10 mobile (VitalThings, Norway), are the investigational devices. These are the same technical devices made in two versions: one wall-mounted (VitalThings Guardian M10 fixed) and one mounted on a trolley (VitalThings Guardian M10 mobile). The Nox T3s and Nonin will be used as comparator devices.
Study NCT06795282 — intervention group
Intervention type: DRUG
Intervention: MTA
Description: MTA is primarily composed of tricalcium silicate, dicalcium silicate, bismuth oxide (for radiopacity), and small amounts of calcium sulfate. MTA is highly biocompatible, making it suitable for use in the root canal system and areas in close contact with tissues.
Study NCT06796465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie with Progressive Postural Control Exercises
Description: The McKenzie Exercises focus on progressive spinal extension to alleviate back pain. Key steps include Extension in Standing, where patients lean backward and return to a neutral stance; Extension in Lying (Partial Range), involving partial pushups in a prone position; and Extension in Lying (Full Range), where patients fully extend their arms to achieve maximum spinal extension. Each movement is held for 1-2 seconds.~The PPCE program enhances core strength and stability through three stages. In the First Stage (2 weeks), core muscles are trained against gravity using movements like pelvic retroversion, crunches, and glute bridges. The Second Stage (3 weeks) incorporates a Swiss ball to challenge trunk muscles with instability. In the Third Stage (3 weeks), a Swiss ball, stretch bands, and a 5 kg sandbag are used to increase complexity on unstable surfaces. Each stage includes six movements, lasting 5 minutes each, for a total session duration of 30 minutes.
Study NCT06796465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie without Progressive Postural Control Exercises
Description: Subject were treated with McKenzie exercises without the addition of Progressive Postural Control Exercises (PPCE).The exercises included the following:~Standing Extension Exercises: Patients leaned backward from a balanced standing position, arching their back before returning to a neutral stance.~Extension in Lying (Partial Range): Performed in a prone position with hands placed under the shoulders, patients lifted their upper torso in a motion similar to a push-up.~Extension in Lying (Full Range): Similar to the partial range extension, but with fully extended arms, aiming for the maximum tolerated extension. Each movement was sustained for 1-2 seconds.
Study NCT06796465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hot Pack
Description: for 10 to 15 minutes
Study NCT06795360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: discontinuation of weight loss medication
Description: Participants will be studied right before their injectable weight loss medication runs out, and 3 months later
Study NCT06796660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nephropathy Formula No. 1
Description: On the basis of integrated treatment for chronic kidney disease (the specific plan is the same as the control group), Nephropathy Formula No. 1 is given orally. The composition and decoction method of the formula are as follows: Bupleurum 10 g, Paeonia lactiflora Pall. 30 g, Scutellaria baicalensis Georgi 12 g, Pinellia ternata (Thunb.) Breit. 12g, Smilax glabra Roxb. 30g, Oldenlandia diffusa (Willd.) Roxb. 30g, Tussilago farfara L. 30g, Poria cocos (Schw.) Wolf 30g, decocted into 300ml, one dose per day, taken warm in two divided doses for 12 weeks.
Study NCT06796660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: integrated basic treatment for chronic kidney disease
Description: dietary nutrition adjustment, blood pressure control, blood sugar control, lipid control, anemia treatment, and regulation of water, electrolyte, and acid-base metabolic balance
Study NCT06796660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: integrated basic treatment for chronic kidney disease
Description: dietary nutrition adjustment, blood pressure control, blood sugar control, lipid control, anemia treatment, and regulation of water, electrolyte, and acid-base metabolic balance
Study NCT06792994 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: The data of this observational trial will be collected as part of routine patient care. Data relating to the time period between the end of participation in the clini-cal first-line trial (CLL13, CLL14, or CLL17) and inclusion in the observational trial will be documented retrospectively at the time point of inclusion in the observa-tional trial. From inclusion in the observational trial, data on survival, long-term efficacy, quality of life, and safety will be collected prospectively
Study NCT06795620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose tissue derived mesenchymal Stroma/stem Cells transplantation
Description: Allogeneic adipose tissue-derived stromal cells (AdMSC) (CellReady ® drug) will be administered intramuscularly into the ischemic limb (dose of 90x10\^6 AdMSC) of patients. They will be followed at 1 day, 7 days, 30 days, 90 days, and 180 days after the injection.
Study NCT05477875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral cannabinoid
Description: dronabinol
Study NCT05477875 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: oral codeine/acetaminophen
Description: 10 tablets of acetaminophen-codeine combination (300-30mg) without refills.
Study NCT05831709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: The intervention consists of a supervised exercise program
Study NCT05831709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: The intervention consists of a supervised exercise program
Study NCT06794944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin (POC)
Description: Vancomycin is glycopeptide antibiotic that has broad gram-positive coverage. Patients will receive 125mg PO every 6 hours for 10 days.
Study NCT06794944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fidaxomicin
Description: Fidaxomicin is a macrolide antibiotic. It is narrow spectrum with potent bactericidal activity specifically against C. difficile. Patients will receive 200mg PO twice daily for 10 days.
Study NCT04711369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium:Yag laser
Description: Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2.~All sensitive/painful areas of the introitus will be treated, using 1-3 repetitions.~In postmenopausal women with signs of atrophy, additional irradiation of the vaginal wall will be performed.
Study NCT04711369 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Erbium:Yag laser
Description: Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same procedures. However, a specially devised placebo probe with a steel shutter, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic irradiation. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use.
Study NCT04606706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health nutrition education intervention
Description: Nutrition education will be given through mobile phone
Study NCT06249698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: meal replacements and supplements
Description: Consumed daily: 2 Nutrimeal Active meal replacement shake, 1 electrolyte replacement drink, 3 metabolism + supplements, 1 whole food meal, and whole food snacks consisting of fruits and vegetables. 1200-1600 calories per day
Study NCT04887584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control diet
Description: The control Typical American Diet (TAD) diet pattern will mimic the level of intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium in the general U.S. population. This diet will feature no servings of pulses per day.
Study NCT04887584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Pulse diet
Description: The Low Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 0.2 cups of pulses per day at 2,000 kilocalories (kcals).
Study NCT04887584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Pulse diet
Description: The High Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 1.5 cups of pulses per day at 2,000 kilocalories (kcals).
Study NCT05623787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted magnetic resonance imaging
Description: See arm description.
Study NCT05457153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Well-Being Process Program (WEBEPROP)
Description: Technology-Based Well-Being Process Program (WEBEPROP)
Study NCT05457153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Well-Being Process Program (WEBEPROP)
Description: Technology-Based Well-Being Process Program (WEBEPROP)